Psychotic disorders and comorbidity: Somatic illness vs. side effect

Psychiatria Danubina

Volumn 21, Issue 3, 2009, Pages 361-367

  Kozumplik, Oliver ^a   Uzun, Suzana ^a   Jakovljević, Miro ^b,c  

^a Psychiatric Hospital Vrap e   (Croatia)

^b KBC Zagreb   (Croatia)

^c UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Antipsychotics; Psychotic disorder; Side effects; Somatic illness

Indexed keywords

ANTIDEPRESSANT AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT;

AKATHISIA; AKINESIA; BRADYKINESIA; CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; COMORBIDITY; CONFERENCE PAPER; DIABETES MELLITUS; DIET; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; GLUCOSE METABOLISM; HEART VENTRICLE ARRHYTHMIA; HEREDITY; HIGH RISK BEHAVIOR; HUMAN; LIFESTYLE; LIPID METABOLISM; METABOLIC DISORDER; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PARKINSON DISEASE; PSYCHOSIS; QT PROLONGATION; SCHIZOPHRENIA; SIDE EFFECT; SOMATIZATION; SUDDEN DEATH; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; CARDIOVASCULAR DISEASES; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DIAGNOSIS, DIFFERENTIAL; HUMANS; NEURODEGENERATIVE DISEASES; SCHIZOPHRENIA;

EID: 70350333477     PISSN: 03535053     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (46)

1. American Psychiatric Association: Practice guideline for the treatment of patients with schizophrenia. 2nd ed. Am J Psychiatry 2004; 161:1-114.
2. Bär KJ, Jochum T, Häger F, Meissner W & Sauer H: Painful hallucinations and somatic delusions in a patient with the possible diagnosis of neuroborreliosis. Clin J Pain 2005; 21:362-363 (Pubitemid 40881148)
3. Bär KJ, Koschke M, Boettger MK, Berger S, Kabisch A, Sauer H, Voss A & Yeragani VK: Acute psychosis leads to increased QT variability in patients suffering from schizophrenia. Schizophr Res 2007; 95:115-123 (Pubitemid 47313634)
4. Blonde L, Kan HJ, Gutterman EM, L'Italien GJ, Kim MS, Hanssens L & McQuade RD: Predicted risk of diabetes and coronary heart disease in patients with schizophrenia: aripiprazole versus standard of care. J Clin Psychiatry 2008; 69:741-748 (Pubitemid 351838683)
5. Bushe C & Holt R: Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia. Br J Psychiatry 2004; 184:S67-71. (Pubitemid 38482546)
6. Chabroux S, Haffen E & Penfornis A: (Diabetes and second-generation (atypical) antipsychotics.) Ann Endocrinol (Paris). 2009 Aug 21. (Epub ahead of print)
7. Chou KL, Borek LL & Friedman JH: The management of psychosis in movement disorder patients. Expert Opin Pharmacother 2007; 8:935-943 (Pubitemid 351227481)
8. Citrome L & Vreeland B: Schizophrenia, obesity, and antipsychotic medications: what can we do? Postgrad Med 2008; 120:18-33.
9. Corrêa BB, Xavier M & Guimarães J: Association of Huntington's disease and schizophrenia-like psychosis in a Huntington's disease pedigree. Clin Pract Epidemol Ment Health 2006; 2:1.
10. Cubeddu LX: QT prolongation and fatal arrhythmias: a review of clinical implications and effects of drugs. Am J Ther 2003; 10:452-457
11. de Hert M, Schreurs V, Nancampfort D & van Winkel R: Metabolic syndrome in people with schizophrenia: a review. World Psychiatry 2009; 8:15-22.
12. Fagiolini A & Goracci A: The effects of undertreated chronic medical illnesses in patients with severe mental disorders. J Clin Psychiatry 2009; 70:22-29
13. Gupta MA & Gupta AK: Psychiatric and psychological co-morbidity in patients with dermatologic disorders: epidemiology and management. Am J Clin Dermatol 2003; 4:833-842 (Pubitemid 38030859)
14. Gury C. [Schizophrenia, diabetes mellitus and antipsychotics]. Encephale 2004; 30:382-391
15. Hennessy S, Bilker WB, Knauss JS, Margolis DJ, Kimmel SE, Reynolds RF, Glasser DB, Morrison MF & Strom BL: Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. BMJ 2002; 325:1070. (Pubitemid 35351800)
16. Irvin MR, Weiner HW, Perry RP, Savage RM & Go RC: Genetic risk factors for type 2 diabetes with pharmacologic intervention in African-American patients with schizophrenia or schizoaffective disorder. Schizophr Res 2009 Jul 28. [Epub ahead of print]
17. Jakovljević M, Crncevic Z, Ljubičić Crossed D sign, Babić D, Topić R & Šarić M: Mental disorders and metabolic syndrome: a fatamorgana or warning reality? Psychiatr Danub 2007; 19:76-86.
18. Jakovljević M, Reiner Z & Miličić D: Mental disorders, treatment response, mortality and serum cholesterol: a new holistic look at old data. Psychiatr Danub 2007; 19:270-281
19. Jindal RD, Keshevan MS, Eklund K Stevens A, Montrose DM & Yeragani VK: Beat-to-beat heart rate and QT interval variability in first episode neuroleptic-naive psychosis. Schizophr Res 2009; 113:176-180
20. Kane JM & Lieberman JA: Adverse effects of psychotropic drugs. New York: Guilford, 1992.
21. Koponen H, Aläräisänen A, Saari K, Pelkonen O, Huikuri H, Raatikainen MJ, Savolainen M & Isohanni M: Schizophrenia and sudden cardiac death: a review. Nord J Psychiatry 2008; 62:342-345
22. Kozumplik O & Uzun S: Recommendations from treatment guidelines for schizophrenia regarding monitoring of side effects of antipsychotics: brief review. Psychiatria Danubina 2009; 21:95-98
23. Lambert TJ, Velakoulis D & Pantelis C: Medical comorbidity in schizophrenia. Med J Aust 2003; 178:S67-70.
24. McElroy SL: Obesity in patients with severe mental illness: overview and management. J Clin Psychiatry 2009; 70:12-21.
25. McIntyre RS: Overview of managing medical comorbidities in patients with severe mental illness. J Clin Psychiatry 2009; 70:e17.
26. Meyer JM & Stahl SM: The metabolic syndrome and schizophrenia. Acta Psychiatr Scand 2009; 119:4-14.
27. National Institute for Clinical Excellence: Guidance on the Use of Newer (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia. Technology Appraisal Guidance 43. London: NICE, 2002.
28. Newcomer JW: Metabolic syndrome and mental illness. Am J Manag Care 2007; 13: S170-7.
29. Newcomer JW: Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19:1-93. (Pubitemid 40677047)
30. Oud MJ & Meyboom-de Jong B: Somatic diseases in patients with schizophrenia in general practice: their prevalence and health care. BMC Fam Pract 2009; 10:32.
31. Pappa S & Dazzan P: Spontaneous movement disorders in antipsychotic-naive patients with first-episode psychoses: a systematic review. Psychol Med 2009; 39:1065-1076
32. Perez-Iglesias R, Crespo-Faccoro B, Amada JA, Garcia Unzueta MT, Ramirez-Bonilla ML, Gonzales-Blanch C, Martinez-Garcia O & Vazquez-Barquero JL: A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone. J Clin Psychiatry 2007; 68:1733-1740 (Pubitemid 350247503)
33. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders: Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Australian and New Zealand Journal of Psychiatry 2005; 39:1-30.
34. Ruetsch O, Viala A, Bardou H, Martin P & Vacheron MN: (Psychotropic drugs induced weight gain: a review of the literature concerning epidemiological data, mechanisms and management). Encephale 2005; 31:507-516
35. Ryan MC, Collins P & Thakore JH: Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003; 160:284-289 (Pubitemid 41110453)
36. Sadock BJ & Sadock VA: Kaplan & Sadock's Concise Textbook of Clinical Psychiatry. Third Edition. Philadelphia: Lippincott Williams & Wilkins, a Wolters Kluwer business, 2008.
37. Sharpe JK & Hills AP: Atypical antipsychotic weight gain: a major clinical challenge. Aust NZ J Psychiatry 2003; 37:705-709
38. Sidouri S & Antzelevitch C: Sudden cardiac death secondary to antidepressant and antipsychotic drugs. Expert Opin Drug Saf 2008; 7:181-194
39. Stahl SM, Mignon L & Meyer JM: Which comes first: atypical antipsychotic treatment or cardiometabolic risk? Acta Psychiatr Scand 2009; 119:171-179
40. Tsuang D, Almqvist EW, Lipe H, Strgar F, DiGiacomo L, Hoff D, Eugenio C, Hayden MR & Bird TD: Familial aggregation of psychotic symptoms in Huntington's disease. Am J Psychiatry 2000; 157:1955-1959
41. Uzun S, Kozumplik O, Mimica N & Folnegović-Šmalc V: Nuspojave psihofarmaka. Zagreb: Medicinska naklada, Psihijatrijska bolnica Vrapče, 2005.
42. Van Gaal LF. Long-term health considerations in schizophrenia: metabolic effects and the role of abdominal adiposity. Eur Neuropsychopharmacol 2006; 16:S142-8.
43. Weber NS, Cowan DN, Millikan AM & Niebuhr DW: Psychiatric and general medical conditions comorbid with schizophrenia in the National Hospital Discharge Survey. Psychiatr Serv 2009; 60:1059-1067
44. Williams-Gray CH, Foltynie T, Lewis SJ & Barker RA: Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options. CNS Drugs 2006; 20:477-505. (Pubitemid 43830737)
45. Wolters ECh: PD-related psychosis: pathophysiology with therapeutical strategies. J Neural Transm Suppl 2006; (71):31-37
46. Zahodne LB & Fernandez HH: Pathophysiology and treatment of psychosis in Parkinson's disease: a review. Drugs Aging 2008; 25:665-682